Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide

William E. Truog, Philip L. Ballard, Michael Norberg, Sergio Golombek, Rashmin C. Savani, Jeffrey D. Merrill, Lance A. Parton, Avital Cnaan, Xianqun Luan, Roberta A. Ballard

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE. We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators. METHODS. As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1β, interleukin-8, transforming growth factor-β, N-acetylglucosaminidase, 8-epi-prostaglandin F, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A. RESULTS. At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks. CONCLUSIONS. Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.

Original languageEnglish (US)
Pages (from-to)670-678
Number of pages9
JournalPediatrics
Volume119
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Premature Infants
Nitric Oxide
Bronchopulmonary Dysplasia
Dinoprost
Placebos
Gases
Secretory Component
Acetylglucosaminidase
Transforming Growth Factors
Hyaluronic Acid
Interleukin-8
Interleukin-1
Immunoglobulin A
Lung Diseases
Pneumonia
Chronic Disease
Therapeutics
Proteins

Keywords

  • Bronchopulmonary dysplasia
  • Inflammation
  • Nitric oxide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Truog, W. E., Ballard, P. L., Norberg, M., Golombek, S., Savani, R. C., Merrill, J. D., ... Ballard, R. A. (2007). Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics, 119(4), 670-678. https://doi.org/10.1542/peds.2006-2683

Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. / Truog, William E.; Ballard, Philip L.; Norberg, Michael; Golombek, Sergio; Savani, Rashmin C.; Merrill, Jeffrey D.; Parton, Lance A.; Cnaan, Avital; Luan, Xianqun; Ballard, Roberta A.

In: Pediatrics, Vol. 119, No. 4, 04.2007, p. 670-678.

Research output: Contribution to journalArticle

Truog, WE, Ballard, PL, Norberg, M, Golombek, S, Savani, RC, Merrill, JD, Parton, LA, Cnaan, A, Luan, X & Ballard, RA 2007, 'Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide', Pediatrics, vol. 119, no. 4, pp. 670-678. https://doi.org/10.1542/peds.2006-2683
Truog, William E. ; Ballard, Philip L. ; Norberg, Michael ; Golombek, Sergio ; Savani, Rashmin C. ; Merrill, Jeffrey D. ; Parton, Lance A. ; Cnaan, Avital ; Luan, Xianqun ; Ballard, Roberta A. / Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. In: Pediatrics. 2007 ; Vol. 119, No. 4. pp. 670-678.
@article{b29d84e814fa44649d9a181604eaeaf9,
title = "Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide",
abstract = "OBJECTIVE. We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators. METHODS. As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1β, interleukin-8, transforming growth factor-β, N-acetylglucosaminidase, 8-epi-prostaglandin F2α, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A. RESULTS. At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F2α levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks. CONCLUSIONS. Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.",
keywords = "Bronchopulmonary dysplasia, Inflammation, Nitric oxide",
author = "Truog, {William E.} and Ballard, {Philip L.} and Michael Norberg and Sergio Golombek and Savani, {Rashmin C.} and Merrill, {Jeffrey D.} and Parton, {Lance A.} and Avital Cnaan and Xianqun Luan and Ballard, {Roberta A.}",
year = "2007",
month = "4",
doi = "10.1542/peds.2006-2683",
language = "English (US)",
volume = "119",
pages = "670--678",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide

AU - Truog, William E.

AU - Ballard, Philip L.

AU - Norberg, Michael

AU - Golombek, Sergio

AU - Savani, Rashmin C.

AU - Merrill, Jeffrey D.

AU - Parton, Lance A.

AU - Cnaan, Avital

AU - Luan, Xianqun

AU - Ballard, Roberta A.

PY - 2007/4

Y1 - 2007/4

N2 - OBJECTIVE. We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators. METHODS. As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1β, interleukin-8, transforming growth factor-β, N-acetylglucosaminidase, 8-epi-prostaglandin F2α, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A. RESULTS. At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F2α levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks. CONCLUSIONS. Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.

AB - OBJECTIVE. We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators. METHODS. As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1β, interleukin-8, transforming growth factor-β, N-acetylglucosaminidase, 8-epi-prostaglandin F2α, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A. RESULTS. At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F2α levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks. CONCLUSIONS. Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.

KW - Bronchopulmonary dysplasia

KW - Inflammation

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=34147134592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147134592&partnerID=8YFLogxK

U2 - 10.1542/peds.2006-2683

DO - 10.1542/peds.2006-2683

M3 - Article

C2 - 17403837

AN - SCOPUS:34147134592

VL - 119

SP - 670

EP - 678

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -